Trial · NCT01702571
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Adverse Events of Primary Interest (AEPIs) | Baseline up to approximately 7 years | The safety population included all participants who had received at least 1 dose of study medication. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Specific AEPIs | Baseline up to approximately 7 years | The safety population included all participants who had received at least 1 dose of study medication. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Adverse Events of Special Interest (AESIs) | Baseline up to approximately 7 years | The safety population included all participants who had received at least 1 dose of study medication. | Percentage of Participants | NUMBER |
| SECONDARY | Progression-Free Survival According to Response Evaluation for Solid Tumors (RECIST) Version (v) 1.1 As Per Investigator Assessment | Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) | Intent to Treat (ITT) Population included all participants enrolled in the study. | months | MEDIAN |
| SECONDARY | Overall Survival | Baseline until death (up to approximately 7 years) | ITT Population included all participants enrolled in the study. | months | MEDIAN |
| SECONDARY | Percentage of Participants With Best Overall Response (Complete Response [CR] or Partial Response [PR]) According to RECIST v 1.1 As Per Investigator Assessment | Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) | ITT Population included all participants enrolled in the study. Only participants with measurable disease were included in the analysis. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Benefit (CR or PR or Stable Disease [SD]) According to RECIST v 1.1 | Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) | ITT Population included all participants enrolled in the study. Only participants with measurable disease were included in the analysis. | Percentage of Participants | NUMBER |
| SECONDARY | Duration of Response (DOR) According to RECIST v 1.1 | Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) | ITT Population included all participants enrolled in the study. Only participants with measurable disease were included in the analysis. | months | MEDIAN |
| SECONDARY | Time to Response According to RECIST v 1.1 | Baseline up to disease progression or death due to any cause, whichever occurs first (assessed every 12 weeks during treatment period thereafter 28-42 days after the last dose or every 3-6 months up to approximately 7 years) | ITT Population included all participants enrolled in the study. Only responders were included in the analysis. | months | MEDIAN |
| SECONDARY | Number of Hospital Visits | Baseline up to approximately 7 years | The safety population included all participants who had received at least 1 dose of study medication. | Number of Hospital Visits | MEAN |
| SECONDARY | Type of Hospital Visits | Baseline up to approximately 7 years | The safety population included all participants who had received at least 1 dose of study medication. | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01702571/outcomes